Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

ENGLEWOOD CLIFFS, NJ–(Marketwired – March 12, 2018) – Immune Pharmaceuticals, Inc.(NASDAQ: IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today the acceptance of an abstract for a poster presentation at the 2018 Pre-IID Pemphigus and Pemphigoid Symposium: “A New Era of Translation and Clinical Science,” being held May 15-16, 2018 in Orlando, FL. The poster, entitled “A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-Eotaxin-1 Antibody, in Bullous Pemphigoid,” detailing interim results from the Company’s ongoing phase 2a trial, will be available for viewing during the poster sessions.

In addition, results of the study will be presented by Neil Korman, MD, PhD, Director Clinical Trials Unit and the Murdough Family Center for Psoriasis, University Hospitals Cleveland Medical Center, and Professor of Dermatology, Case Western Reserve University School of Medicine, in an oral presentation entitled “Targeting eosinophils in bullous pemphigoid,” on Tuesday, May 16, at 2:45 p.m. ET. Dr. Korman is a member of the Company’s Scientific Advisory Board.

Tony Fiorino, MD, PhD, Immune’s Chief Medical and Operating Officer, noted, “We are gratified to have the opportunity to present these results in a forum devoted exclusively to the care of patients with autoimmune blistering diseases, following the well-received late-breaker presentation at the American Academy of Dermatology Annual Meeting last month. We expect to conclude enrollment of this study in the near future, allowing us to proceed with our plans for an end of phase 2 meeting with the FDA.”

About Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including atopic dermatitis, immune and inflammatory hepatitis, and asthma.

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this news release made by representatives of Immune relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune’s product candidates and the sufficiency of Immune’s cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune’s ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that Immune will successfully complete its anticipated corporate restructuring, filing of the Form 10, or consummation of the spin-off of Cytovia, or that Immune will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. Immune may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune’s board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune’s filings with the Securities and Exchange Commission, including those discussed in Immune’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and periodic reports filed on Form 8-K.

SOURCE Immune Pharmaceuticals Inc.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475